IGC Pharma, Inc.
IGC
$0.32
$0.000.72%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -53.64% | 20.59% | 11.86% | 25.98% | 41.58% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -53.64% | 20.59% | 11.86% | 25.98% | 41.58% |
| Cost of Revenue | -57.01% | 59.63% | 41.94% | 115.49% | 82.91% |
| Gross Profit | -50.00% | -5.52% | -9.94% | -21.80% | 13.79% |
| SG&A Expenses | 35.45% | -26.70% | -72.27% | -49.28% | -25.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.27% | -15.59% | -44.19% | -33.32% | -21.93% |
| Operating Income | -64.72% | 19.75% | 49.86% | 37.36% | 29.35% |
| Income Before Tax | -6.06% | 32.76% | 58.51% | 67.28% | 29.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.06% | 32.76% | 58.51% | 67.28% | 29.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.06% | 32.76% | 58.51% | 67.28% | 29.95% |
| EBIT | -64.72% | 19.75% | 49.86% | 37.36% | 29.35% |
| EBITDA | -72.14% | 20.24% | 52.47% | 39.36% | 30.78% |
| EPS Basic | 11.06% | 40.98% | 66.59% | 73.09% | 49.89% |
| Normalized Basic EPS | 10.64% | 40.59% | 65.16% | 49.48% | 50.00% |
| EPS Diluted | 11.06% | 40.98% | 66.59% | 73.09% | 49.89% |
| Normalized Diluted EPS | 10.64% | 40.59% | 65.16% | 49.48% | 50.00% |
| Average Basic Shares Outstanding | 19.01% | 14.03% | 23.88% | 21.82% | 39.97% |
| Average Diluted Shares Outstanding | 19.01% | 14.03% | 23.88% | 21.82% | 39.97% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |